|
ABclonal Biotechnology
acetyl p53 Acetyl P53, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/Acetyl-p53-K382+Rabbit+mAb/pm42988015-195-12-14 Average 93 stars, based on 1 article reviews
acetyl p53 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
p53 ![]() P53, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/p53/pmc13768926-148-34-37 Average 96 stars, based on 1 article reviews
p53 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
ABclonal Biotechnology
p53 ![]() P53, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/p53+Rabbit+pAb/pm42988015-195-8-10 Average 95 stars, based on 1 article reviews
p53 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
mouse α p53 ![]() Mouse α P53, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/p53/pmc13772693-339-4-13 Average 96 stars, based on 1 article reviews
mouse α p53 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
mouse anti p53 ![]() Mouse Anti P53, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/p53+(DO-1)+Mouse+mAb/pmc13768205-103-7-10 Average 95 stars, based on 1 article reviews
mouse anti p53 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Proteintech
mouse anti p53 ![]() Mouse Anti P53, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/P53+Antibody/pmc13757698-65-7-17 Average 96 stars, based on 1 article reviews
mouse anti p53 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Cell Signaling Technology Inc
anti p53 ![]() Anti P53, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/p53+Mouse+mAb/pmc13748930-57-22-26 Average 96 stars, based on 1 article reviews
anti p53 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Proteintech
anti p53 ![]() Anti P53, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/P53+Antibody/pm42998704-206-9-13 Average 96 stars, based on 1 article reviews
anti p53 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Proteintech
p53 ![]() P53, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+p53/P53+Antibody/pmc13757581-259-22-23 Average 96 stars, based on 1 article reviews
p53 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
Journal: BioMed Research International
Article Title: Apoptosis‐Inducing and Cytotoxic Effects of the Daphne mucronata Extract and Its Bioactive Compound Gnidilatimonoein in Liver Cancer Cells
doi: 10.1155/bmri/3638482
Figure Lengend Snippet: The relative expression levels of proapoptotic and antiapoptotic proteins assessed by Western blotting. The relative expression levels of proapoptotic and antiapoptotic proteins were evaluated in HepG 2 cells following treatment with GND, 3.439 μ g/mL. Two groups were analyzed: (a) untreated control cells and (b) GND‐treated cells. The expression of Bax, P53, cleaved caspase‐3, and Bcl‐2 was assessed by Western blotting and normalized to GAPDH, which served as the internal loading control. Normalization was performed by adjusting each target protein′s band intensity relative to GAPDH to ensure accurate comparison among samples. Representative Western blot images are shown, with each panel depicting one of the analyzed proteins. Quantitative data are expressed as mean ± SEM. Statistical significance among the five relative‐expression fold‐changes was assessed by one‐way ANOVA; for each protein, the GND‐treated group was subsequently compared with its own untreated control, with different letters within each protein pair denoting a statistically significant difference ( p < 0.0001). GND treatment markedly upregulated the proapoptotic proteins Bax, P53, and cleaved caspase‐3, while significantly downregulating the antiapoptotic protein Bcl‐2, resulting in a pronounced increase in the Bax/Bcl‐2 ratio, consistent with activation of the intrinsic apoptotic pathway. Abbreviations: GND, gnidilatimonoein; GAPDH, glyceraldehyde‐3‐phosphate dehydrogenase.
Article Snippet: The membranes were blocked with 5% nonfat dry milk in Tris‐buffered saline with 0.1% Tween‐20 (TBST) for 1 h at room temperature, followed by overnight incubation at 4°C with primary antibodies against Bax, Bcl‐2,
Techniques: Expressing, Western Blot, Control, Comparison, Activation Assay, Significance Assay
Journal: Aging Cell
Article Title: Excessive COX ‐Prostaglandin Signaling Promotes Cellular Senescence and Impaired Skeletal Muscle Recovery in Aging
doi: 10.1111/acel.70843
Figure Lengend Snippet: RT‐qPCR primer sequences.
Article Snippet: Cells were incubated overnight at 4°C with
Techniques:
Journal: Aging Cell
Article Title: Excessive COX ‐Prostaglandin Signaling Promotes Cellular Senescence and Impaired Skeletal Muscle Recovery in Aging
doi: 10.1111/acel.70843
Figure Lengend Snippet: COX‐prostaglandin pathway activation correlates with senescence burden during impaired muscle recovery in aged mice. (A) Representative images of SA‐β‐Gal counterstained with H&E histology in gastrocnemius muscle from young and old mice at RL7. Quantitative analysis in gastrocnemius of young and old mice at AMB, HU, RL2, RL4, and RL7 ( n = 3–10/group and time point). (B) Correlation analysis of SA‐β‐Gal + /Area (μm 2 ) and gastrocnemius muscle mass (mg) in young and old mice at RL7 ( n = 6–7). (C–E) mRNA level of Senescence markers (p53, p21, p16) by RT‐qPCR at AMB, HU, RL2, RL4, and RL7 ( n = 4–6/group and time point). (F–J) mRNA level of SASP associated markers (PAI‐1, IFN‐γ, Igfbp4, IL‐6, IL‐1β) by RT‐qPCR at AMB, HU, RL2, RL4, and RL7 ( n = 4–6/group and time point). (K) Correlation analysis of gastrocnemius mass and the COX pathway with major downstream oxylipins (PGE2, PGF2α, TxB2) at RL4. Pearson's correlation, with corresponding p ‐values, r , and R 2 displayed on the graph ( n = 6/group). (L) Correlation analysis of gastrocnemius mass and the COX pathway with major downstream oxylipins (PGE2, PGF2α, TxB2) at RL7. Pearson's correlation, with corresponding p ‐values, r , and R 2 displayed on the graph ( n = 6/group). (M) Correlation analysis of SA‐β‐Gal + /Area (μm 2 ) and the COX pathway with major downstream oxylipins (PGE2, PGF2α, TxB2) at RL4. Pearson's correlation, with corresponding p ‐values, r and R 2 displayed on the graph ( n = 3/group and timepoint). (N) mRNA level of Ptger1 by RT‐qPCR at AMB, HU, RL2, RL4, and RL7 ( n = 4–6/group and timepoint). (O) mRNA level of Ptges‐1 by RT‐qPCR at AMB, HU, RL2, RL4, and RL7 ( n = 4–6/group and timepoint). (P) Correlation analysis of senescence (p53, p21, p16) and SASP associated markers (PAI‐1, IFN‐γ, Igfbp4, IL‐6, IL‐1β), mRNA level and Ptges mRNA level at RL7. Pearson's correlation, with corresponding p ‐values, r and R 2 displayed on the graph ( n = 5/group). Statistical analysis: All data presented as mean ± SEM. Statistical analyses were performed using two‐way ANOVA followed by Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. (*) indicates a group difference at a specific time point. # p < 0.05, ## p < 0.01, ### p < 0.001, and #### p < 0.0001. (#) indicates a within group difference from their baseline time point. Correlations were evaluated using Pearson's correlation. Cell specific identification is indicated by a black arrow. Scale bar 30 μm.
Article Snippet: Cells were incubated overnight at 4°C with
Techniques: Activation Assay, Histology, Analysis, Quantitative RT-PCR
Journal: Aging Cell
Article Title: Excessive COX ‐Prostaglandin Signaling Promotes Cellular Senescence and Impaired Skeletal Muscle Recovery in Aging
doi: 10.1111/acel.70843
Figure Lengend Snippet: COX inhibition improves recovery and attenuates senescent cell accumulation and fibrosis during reloading in aged mice. (A) Experimental study design, Old (~25 month) male C57BL/6 mice underwent 14 days of hindlimb unloading followed by 7 days of reloading. At reload, mice were intraperitoneally (IP) injected with Saline, High‐ or low‐dose COX‐inhibitor ( n = 7–12/group). (B) mRNA level of key prostaglandin‐signaling genes, Ptges‐1 and Ptger1 by RT‐qPCR at RL7 in gastrocnemius, shown as mean ( n = 5/group). (C) Whole‐body grip strength normalized to body weight in Saline, High or Low‐dose COX‐inhibitor at RL7 ( n = 7–12/group). (D) Gastrocnemius mass of Saline, High or Low‐dose COX‐inhibitor at RL7 ( n = 7–12/group). (E) Soleus mass of Saline, High or Low‐dose COX‐inhibitor at RL7 ( n = 7–12/group). (F) Ex vivo soleus specific force frequency (mN/mm 2 ) from 10 to 200 Hz of Saline and Low dose ( n = 11–12). (G) Ex vivo soleus specific force frequency (mN/mm 2 ) from 10 to 200 Hz of Saline and High dose ( n = 6–11). (H) Representative images and quantification of Sirius red staining in the gastrocnemius of Saline, High or Low‐dose COX‐inhibitor at RL7 ( n = 7–12/group). (I) Representative images and quantification of SA‐β‐gal counterstained with H&E histology in gastrocnemius muscle Saline, High or Low‐dose COX‐inhibitor at RL7 ( n = 7–12/group). (J) Representative images and quantification of γH2AX + in gastrocnemius muscle, Saline, High or Low‐dose COX‐inhibitor at RL7 ( n = 7–12/group). (K) Representative images and quantification of p21 + in gastrocnemius muscle Saline, High or Low‐dose COX‐inhibitor at RL7 ( n = 7–12/group). (L) mRNA level of senescent markers, p53, p21, p16 INKA by RT‐qPCR at RL7 in gastrocnemius, shown as mean ( n = 5/group). (M) mRNA level of SASP markers, PAI‐1, Igfbp4, IL‐1β, IL‐6, IFN‐γ, TNF‐α, Ccl2, Ccl8, Cxcl10, Timp2, Col3a1 by RT‐qPCR at RL7 in gastrocnemius, ( n = 5/group). Statistical analysis: All data presented as mean ± SEM. Data represent biologically independent muscle samples. * p < 0.05, ** p < 0.01, and *** p < 0.001, as determined by one‐way ANOVA followed by Tukey's multiple comparisons test. Statistical analyses were performed with a two‐way ANOVA and Tukey's multiple comparison test F and G. Cell‐specific identification is indicated by a white or black arrow. Scale bar 30 μm.
Article Snippet: Cells were incubated overnight at 4°C with
Techniques: Inhibition, Injection, Saline, Quantitative RT-PCR, Ex Vivo, Picrosirius Red Staining, Histology, Analysis, Comparison, H&E Stain
Journal: Aging Cell
Article Title: Excessive COX ‐Prostaglandin Signaling Promotes Cellular Senescence and Impaired Skeletal Muscle Recovery in Aging
doi: 10.1111/acel.70843
Figure Lengend Snippet: Senescent macrophages drive COX‐2‐dependent PGE2 production and induce myotube atrophy via secreted factors. (A) Experimental design of the doxorubicin (DOX)‐induced senescence protocol in C2C12 myoblasts, RAW 264.7 macrophages, and NOR‐10 fibroblasts. Cells were treated with DOX (0.1 μM, 24 h) followed by a 3‐day incubation. (B) Representative images of senescence‐associated β‐galactosidase (SA‐β‐Gal) staining in control (CON) and DOX‐treated C2C12, RAW 264.7, and NOR‐10 cells. (C) Prostaglandin E2 (PGE2) concentration measured by ELISA in culture media from CON and DOX‐treated C2C12, RAW 264.7, and NOR‐10 cells. (D) Representative immunofluorescence images of RAW 264.7 cells stained for DAPI (nuclei, blue), p53 (red), and cyclooxygenase‐2 (COX‐2, green) under CON and DOX conditions. (E) Experimental design for RAW 264.7 treatment conditions including CON, DOX, DOX + NS‐398 (COX‐2 inhibitor), and Butaprost (EP2 agonist). (F) Representative SA‐β‐Gal staining in RAW 264.7 cells across all treatment groups. (G) Quantification of SA‐β‐Gal‐positive RAW 264.7 cells (%). (H) Experimental design of conditioned media (CM) generation from RAW 264.7 cells treated with CON, DOX, DOX + NS‐398 (COX‐2 inhibitor), and Butaprost (EP2 agonist), followed by treatment of differentiated C2C12 myotubes with CM from each condition. (I) Representative immunofluorescence images of myotubes stained for MyHC (green) and DAPI (blue) following treatment with CM from each condition. (J) Quantification of myotube area (%). The dotted line represents myotubes differentiated under standard differentiation media (DM) conditions. (K) Quantification of fusion index (arbitrary units). The dotted line represents myotubes differentiated under standard differentiation media (DM) conditions. Statistical analysis: All data presented as mean ± SEM. Data represent biologically independent experiments ( n = 6 per group). * p < 0.05, ** p < 0.01 and *** p < 0.001, as determined by one‐way ANOVA followed by Tukey's multiple comparisons test (G, J, K). For PGE2 Elisa measurements, statistical significance was assessed using an unpaired two‐tailed t ‐test. White scale bars: SA‐β‐Gal stain, 10 μm; immunofluorescence (DAPI/p53/COX‐2), 20 μm; MyHC/DAPI images, 200 μm.
Article Snippet: Cells were incubated overnight at 4°C with
Techniques: Incubation, Staining, Control, Concentration Assay, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Analysis, Two Tailed Test
Journal: Cancer Biology & Therapy
Article Title: NRF2 and mutant p53 separately regulate redox balance in esophageal squamous cell carcinoma through metabolic reprogramming
doi: 10.1080/15384047.2026.2745287
Figure Lengend Snippet: The p53 R246W mutant introduced oxidation tolerance in D3 cell independent of NRF2. (A) Immunoblots of total p53 protein accumulation after p53 R246W mutant transfection in D3 cell. (B) Immunofluorescence staining of p53 nuclei localization after p53 R246W mutant transfection in D3 cell. Scale bar 30 μm. (C, D) Cell viability changes of D3 cell to TBHP (C) and ART (D) at gradient concentration after p53 R246W transfection. (E–G) Bioinformatical analysis of associations between TP53 and NFE2L2 alterations and associations of relevant NRF2 downstream genes from the TCGA database. All of the samples were divided into NFE2L2 non-amplification and NFE2L2 amplification groups for the first step, then TP53 was divided into missense mutation group, splice mutation and multi hit group, and nonsense mutation group, followed by corresponding variations of other relevant genes. (H) Immunoblots of CUL3-KEAP1-NRF2 axis and relevant proteins after p53 R246W mutant transfection in D3 cell. * p < 0.05, ** p < 0.01, *** p < 0.001. ART, artesunate. AMP, amplification. DEL, deletion. DBD, DNA-binding domain. ESCC, esophageal squamous cell carcinoma. HNSCC, head and neck squamous cell carcinoma. LUSC, lung squamous cell carcinoma.
Article Snippet: Primary antibodies used were as following: NRF2 (Abcam, ab62352, 1:1000), NQO1 (Proteintech, 67240-1-Ig, 1:10,000), G6PD (Abcam, ab210702, 1:1000), SLC7A11 (Invitrogen, PA1-16893, 1:800),
Techniques: Mutagenesis, Western Blot, Transfection, Immunofluorescence, Staining, Concentration Assay, Analysis, Amplification, Binding Assay
Journal: Cancer Biology & Therapy
Article Title: NRF2 and mutant p53 separately regulate redox balance in esophageal squamous cell carcinoma through metabolic reprogramming
doi: 10.1080/15384047.2026.2745287
Figure Lengend Snippet: EGFR-ERK-ETS1-SLC7A11 axis-mediated GSH anabolism contributed to the antioxidative phenotype of D3-p53 R246W cell. (A) Immunoblots of EGFR-ERK1/2-ETS1-SLC7A11 axis change after p53 R246W mutant transfection in D3 cell. (B) RT-qPCR analysis of Slc7a11 mRNA expression change after p53 R246W mutant transfection in D3 cell. (C) GSH anabolism changes after p53 R246W mutant transfection in D3 cell. (D) Knockdown efficacy of Slc7a11 using RNAi at the protein level in p53 R246W -D3 cell. Based on the result, siSLC7A11-1 was selected for further experiment. (E) Sensitivity variation of p53 R246W -D3 cell to TBHP after Slc7a11 knockdown using RNAi. (F, G) Immunoblots of ETS1 and SLC7A11 change after treatment with p -ERK1/2 activator Sorafenib and p -ERK1/2 inhibitor Trametinib. (H) Knockdown efficacy of Ets1 using RNAi at protein level and the corresponding change tendency of SLC7A11 in p53 R246W -D3 cell. Based on the result, siETS1-1 was selected for further experiment. (I) Sensitivity variation of p53 R246W -D3 cell to TBHP after Ets1 knockdown using RNAi. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Article Snippet: Primary antibodies used were as following: NRF2 (Abcam, ab62352, 1:1000), NQO1 (Proteintech, 67240-1-Ig, 1:10,000), G6PD (Abcam, ab210702, 1:1000), SLC7A11 (Invitrogen, PA1-16893, 1:800),
Techniques: Western Blot, Mutagenesis, Transfection, Quantitative RT-PCR, Analysis, Expressing, Knockdown, Sensitivity